PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-25.63%
Negative ROE while Healthcare median is -3.70%. Seth Klarman would investigate if capital structure or industry issues are at play.
-11.45%
Negative ROA while Healthcare median is -5.73%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-14.18%
Negative ROCE while Healthcare median is -4.74%. Seth Klarman would investigate whether a turnaround is viable.
-145.68%
Negative gross margin while Healthcare median is 45.35%. Seth Klarman would check if the firm is selling below cost.
-12769.14%
Negative operating margin while Healthcare median is -6.09%. Seth Klarman would look for a path to operational turnaround.
-11511.11%
Negative net margin while Healthcare median is -8.35%. Seth Klarman would see if cost cuts or revenue growth can fix losses.